Hutchison China MediTech to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on June 10, 2016

Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event

HONG KONG, June 6, 2016 /PRNewswire/ -- Hutchison China MediTech (LONDON STOCK EXCHANGE: HCM, NASDAQ: HCM) based in China, and globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products., today announced that Chief Executive Officer, Christian Hogg, will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on Jun 10, 2016. This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to US investors.

DATE: June 10th, 2016
TIME: 9.00am ET
LINK: www.adr.db.com/dbvic

This will be a live, interactive online event where investors in the US are invited to ask international companies their questions in real-time and to download a company's information in their "virtual trade booth" in the Exhibits section. If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

Participation is free of charge.

It is recommended that investors pre-register to save time and receive event updates.

Recent Company Highlights

• Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer
• Chi-Med initiates first-in-human clinical trial of novel PI3K inhibitor HMPL-689
• Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market
• Chi-Med initiates sulfatinib Phase III registration study in pancreatic neuroendocrine tumor patients

About Hutchison China MediTech

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: http://www.chi-med.com

Read more: http://www.nasdaq.com/article/hutchison-china-meditech-limited-hcm-interview-withchristian-hoggexecutive-director-andceo-cm603190#ixzz49BwmhNqp

SOURCE Hutchison China MediTech

Related Links

http://www.chi-med.com